Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
Open Access
- 12 February 2020
- journal article
- research article
- Published by Springer Nature in AIDS and Behavior
- Vol. 24 (9) , 2520-2531
Abstract
Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninfected males and females in sequentially-enrolled cohorts of two dosing strategies. We compared acceptability of product attributes, prevention preferences and future interest in injectable PrEP (FIIP) by region, sex-at-birth, arm and cohort and used multivariable analysis to identify FIIP determinants. Baseline injectable PrEP preferences were higher in non-U.S. sites and increased in both regions over time. In multivariable models, FIIP was most strongly associated with acceptability of product attributes, was higher in non-U.S. sites and more altruistic participants. Treatment arm and report of pain were not associated with FIIP. Injectable acceptability was highest in non-U.S. sites. Preferences for injectable versus other PrEP methods were higher among U.S. males than females, but higher among males and females in non-U.S. settings.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (UM1AI068619, UM1AI068617)
- District of Columbia Developmental Center for AIDS Research (AI117970)
This publication has 33 references indexed in Scilit:
- A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence?BMC Infectious Diseases, 2018
- HIV Preexposure Prophylaxis, by Race and Ethnicity — United States, 2014–2016MMWR. Morbidity and Mortality Weekly Report, 2018
- Effectiveness and safety of oral HIV preexposure prophylaxis for all populationsAIDS, 2016
- The preexposure prophylaxis revolution; from clinical trials to programmatic implementationCurrent Opinion in HIV and AIDS, 2016
- Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2015
- Study Product Adherence Measurement in the iPrEx Placebo-Controlled TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenNew England Journal of Medicine, 2012
- Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2012
- Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 TransmissionScience Translational Medicine, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010